Revolutionising Health Diagnostics

Detecting chronic illnesses such as cancer has traditionally relied on invasive and costly methods, but DrNose is introducing an alternative that could make early screening for diagnostics more accessible and affordable.

DrNose has developed an Electronic Nose, a small, portable device that analyses a person’s breath to detect signs of diseases. The device uses six highly specialised sensors to identify chemical molecules linked to conditions such as breast and lung cancers, diabetes, and other chronic diseases. Despite its compact design, the device has achieved an accuracy of 90+% in initial clinical trials conducted at institutions such as Ben Gurion University and the University of New South Wales.

This technology is the result of two decades’ worth of research, blending expertise in medicine, electronics, and AI. While animal noses can have millions of receptors — dogs, for instance, have 300 million — the DrNose device uses just six optimised sensors. These sensors work with proprietary algorithms to deliver precise results.

DrNose’s focus is not just on accuracy but also on accessibility. The device is designed to be affordable and easy to use, making it suitable for rural areas where access to healthcare can be limited. It can also serve as an early health indicator for insurance purposes, helping assess risk quickly and effectively.

Looking ahead, we plan to launch an improved version of the device in 2025, aiming to expand our reach to consumer healthcare markets and eventually to hospitals and clinics following regulatory approvals. We are also exploring partnerships to accelerate clinical trials and adapt the technology for additional diseases.

With a proven track record in association with iOmniscient, our parent company, DrNose offers a practical and innovative tool to improve health outcomes worldwide.

For more information, visit DrNose.ai.